|
Published by: SMI Publishing, Ltd
Published: Jan. 31, 2007
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Nitin Damle, Director, Oncology Research, Wyeth Pharmaceuticals.
- 9.10 MODULAR TIME-TO-MARKET PROCESS DEVELOPMENT CONCEPT FOR MONOCLONAL ANTIBODIES
- Choice of expression system
- Media development
- High titer fermentation technology
- High yield downstream processing
- Process validation oriented at clinical success
- Scalability and robustness of pilot scale
- Royalty load for in-licensed IP
- Rolf G Werner, Head, Corporate Division Biopharmaceuticals, Boehringer-Ingelheim .
- 9.50 IMPROVING EFFECTOR FUNCTIONS OF ANTIBODIES
- Enhancing the clinical success of therapeutic antibodies
- Variety of genetic engineering methods used to enhance effector function of an antibody in order to suit the strategy for its clinical application
- Structural basis of antibody effector function
- Superior specific target cell killing in vitro and in vivo
- Increasing the potency of antibodies regardless of the receptor phenotype
- Substantial clinical benefits when used with therapeutic antibodies
- Yielding better results
- Peter Sondermann, Head, Process Biochemistry, GLYCART biotechnology (part of the Roche group).
- 10.30 Morning Coffee
- 10.50 SYNTHETIC HUMAN ANTIBODIES
- Development of antagonists and agonists of signalling pathways
- Design principles for highly functional antibody libraries
- Structure-based design of antibody diversity
- Selection and formatting strategies for antagonist and agonist activity
- High throughput analysis and production of novel antibodies
- Applications for controlling cell proliferation and cell death
- Sachdev Sidhu, Senior Scientist, Genentech Inc.
- 11.30 THERAPEUTIC ANTIBODY DISCOVERY
- A portfolio view
- Comparing and contrasting the complementary technologies of phage and ribosome display
- Their key usage in therapeutic antibody discovery strategy
- Critical success factors
- Diversity of lead antibodies
- Potencies of optimised antibodies
- Tristan Vaughan, Director Discovery, Respiratory & Inflammation, Cambridge Antibody Technology.
- 12.10 Networking Lunch
- 1.40 NANOBODIES AS NEW THERAPEUTIC ENTITIES
- A new generation of protein-based drugs that combine advantages of monoclonal antibodies and small molecule drugs
- Nanobodies: single variable domains derived from camelids
- Picomolar affinity leads by direct sorting of antigen-specific B-cells from immunised llamas
- Examples of designs of nanobody-based protein drugs
- Nanobodies efficacious in animal models of rheumatoid arthritis, cancer and thrombosis
- Advantages of nanobodies compared to monoclonal antibodies
- Easy formatting, tailoring of half-life and low cost of goods
- Hennie Hoogenboom, CSO, Ablynx.
- 2.20 ANTIBODY MANUFACTURING AND PURIFICATION
- The greatest challenge to face the biotech industry?
- Antibody purification methods
- Manufacturing regulatory issues
- Ensuring adequate manufacturing capacity
- Developing strategic plans to ensure they have adequate resources
- Purifying any antibodies quickly and efficiently
- Types of strategies used
- Lothar Jacob, Marketing Manager, Merck KgaA.
- 3.00 Afternoon Tea
- 3.20 HUMAN MONOCLONAL ANTIBODIES FOR PROPHYLAXIS AND THERAPY OF INFECTIOUS DISEASES
- Novel medicines for multi-resistant bacteria and emerging viruses
- Humoral immune response in infectious diseases
- Rapid generation of human mAbs by phage display
- Importance of antigen and assay formats
- Applications and business cases
- Jan ter Meulen, Executive Director, Infectious Diseases, Crucell.
- 4.00 TUMOUR-SPECIFIC ANTIBODY-TARGETED CHEMOTHERAPY USING IMMUNOCONJUGATES OF CALICHEAMICIN
- Antibody-drug conjugates
- Tumour-specific delivery of potent chemotherapeutic agents may be therapeutically beneficial
- Calicheamicin is a potent DNA-minor groove-binding radiomimetic cytotoxic agent
- Strong evidence of anti-tumour efficacy of calicheamicin-conjugated antibodies in various preclinical models
- CD33-specific and targeted Mylotarg®, also known as gemtuzumab ozogamicin, is the first cytotoxic immunoconjugate to be approved by the US FDA and has provided the first clinical proof of concept in the treatment of patients with relapsed acute myeloid leukaemia
- CD22-specific inotuzumab ozogamicin is presently in advanced stage of clinical evaluation in patients with relapsed B -cell non-Hodgkin’s lymphoma and has demonstrated clinical activity with reversible and manageable side effects profile
- A number of targeting opportunities with immunoconjugates of calicheamicin specific for solid tumors being explored are in various stages of preclinical advancement
- Nitin Damle, Director, Oncology Research, Wyeth Pharmaceuticals.
- 5.20 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Re-registration & Coffee
- 9.00 Chairman's Opening Remarks
- Joseph Bolen, CSO, Millennium Pharmaceuitcals Inc.
- 9.10 TOXIN-CONJUGATED APPROACHES FOR ANTIBODY-BASED CANCER THERAPEUTICS
- Status report on efficacy and side effect relationships
- Target selection
- Antibody generation
- Toxin and linker selection
- Preclinical efficacy and safety assessments
- Clinical experience
- Joseph Bolen, CSO, Millennium Pharmaceuitcals Inc.
- 9.50 ENGINEERING DESIRABLE MODIFICATIONS ON THERAPEUTIC ANTIBODIES
- Designing and engineering desirable biological activity and affinity
- Humanise or germline rodent or human antibodies with less immunogenicity
- Engineer lead antibodies with less aggregation issues
- Modify lead antibodies with better expression
- Engineer lead antibodies with better stability
- W.David Shen, Director, Amgen.
- 10.30 Morning Coffee
- 11.00 FUNCTIONAL DIFFERENCES IN CLASSES OF TNF ANTAGONISTS
- Two classes of biologic agents that target TNF alpha:
- Soluble TNF receptor (Etanercept) and anti-TNF monoclonal antibodies
- All of these agents bear Fc region of IgG1, which has potential to elicit effector functions
- Objective was to assess ability of the TNF antagonists to bind soluble and membrane-bound TNF and to mediate cell killing
- TNF antagonists exhibited functional differences in in-vitro models
- Taruna Arora, Senior Scientist, Amgen.
- 11.40 IMMUNOGENICITY
- Screening in a global context
- Immunogenicity and possible consequences
- Immunogenicity identification and testing
- Current regulatory guidelines
- Addressing the challenges of antibody immunogenicity
- Selected case studies on antibody therapeutics
- Philippe Stas, Chief Operating Officer, AlgoNomics N V.
- 12.20 Networking Lunch
- 1.50 INTELLECTUAL PROPERTY ISSUES
- Review of the intellectual property situation relating to antibodies
- Obtaining patents to antibodies - recent developments in the granting of patents to antibodies
- How to build an antibody patent portfolio
- What is a reasonable scope of protection for an antibody patent claim?
- Strategies for enforcing patents to antibodies
- How to avoid infringing competitor antibody patents
- Potential effects of antibody patents of broad scope on the biotechnology industry
- Stephen Ingham, Patent Attorney, Eli Lilly.
- 2.30 ANTIBODY DISCOVERY AND DEVELOPMENT
- Case study - HUMIRA/ABT-874
- Alejandro Aruffo, Vice President, Global Pharmaceutical Development, Abbott Laboratories.
- 3.10 Afternoon Tea
- 3.40 NATURAL ANTIBODY DERIVATIVES
- Developing the next generation of antibody drugs
- Challenges faced with classical antibodies
- Naturally occurring antibody alternatives
- Advantages of novel antibody format
- Technology involved
- Application in cancer therapy
- Therapeutic application in trypanosomiasis
- Serge Muyldermans, Professor, Vrije Universiteit Brussel.
- 4.20 PRODUCT DEVELOPMENT
- A novel drug platform for cancer therapy
- Basic biology of molecules
- The principle of polyclonal T cell therapy
- Results from clinical trials
- Patrick Bauerle, Chief Scientific Officer & Senior Vice President, Research & Development, Micromet Inc.
- 5.00 Chairman’s Closing Remarks and Close of Conference
AbstractSMi’s 7th Annual Therapeutic Antibodies Conference will provide a forum for leading industry experts from major pharmaceutical companies to discuss and evaluate the latest challenges and problems facing the therapeutic antibodies market.
As one of the fastest growing segments of the pharma market, the value of therapeutic antibodies is expected to more than triple in value. The success of current marketed products has led to escalation in antibody development, with more than 370 programs currently in the pipeline. Evolutions in innovation and business model dynamics will drive the sector's dominant position.
SMi’s Therapeutic Antibodies Conference is a must-attend event and will provide an excellent opportunity to network, enhance your company’s profile and keep you up-to-date on the latest issues in the market.
The two-day conference programme will be delivered by a panel of expert speakers, including:
- Professor Rolf Werner, Head, Corporate Division, Biopharmaceuticals & Corporate Senior Vice President, Boehringer-Ingelheim
- Dr Joseph Bolen, Senior Vice President, Research & Drug Discovery, Millennium Pharmaceuticals
- Dr Nitin Damle, Director, Oncology Discovery Research, Wyeth Pharmaceuticals
- Dr Tristan Vaughan, Director, Discovery, Respiratory & Inflammation, Cambridge Antibody Technology
- Dr W. David Shen, Director, Amgen
- Dr Hennie Hoogenboom, Chief Scientific Officer, Ablynx NV
- Stephen Ingham, Patent Attorney, Eli Lilly
- Dr Jan ter Meulen, Executive Director, Infectious Diseases, Crucell
By attending this conference, you will learn about:
- INTELLECTUAL PROPERTY: The current status of regulations affecting the pharmaceutical industry
- LICENSING ANTIBODIES: Discover how to optimise business opportunities and form strategic collaborations with major companies that result in successful partnerships
- TREATMENTS FOR DISEASE: Hear practical examples and case studies on the innovative uses of antibodies in cancer treatment and what toxin-conjugated approaches for antibody-based therapeutics are doing for the industry
- NOVEL TECHNOLOGIES: See the positive effect new and innovative technologies are having on businesses
- DEVELOPING THE NEXT STAGE OF ANTIBODIES: Review the challenges faced by major pharma companies whilst developing antibodies
- EXCLUSIVE INFORMAL NETWORKING: Collaborate with industry peers in an environment promoting information exchange
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
